key: cord-0951841-fxebqm7k authors: Qiu, C.; Cui, C.; Hautefort, C.; Haehner, A.; Zhao, J.; Yao, Q.; Zeng, H.; Nisenbaum, E. J.; Liu, L.; Zhao, Y.; Zhang, D.; Levine, C. G.; Cejas, I.; Dai, Q.; Zeng, M.; Herman, P.; Jourdaine, C.; With, K. d.; Draf, J.; Chen, B.; Jayaweera, D. T.; Denneny, J. C.; Casiano, R.; Yu, H.; Eshraghi, A. A.; Hummel, T.; Liu, X.; Shu, Y.; Lu, H. title: Olfactory and Gustatory Dysfunction as An Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study date: 2020-05-16 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.05.13.20100198 sha: d3e7ec04c24315ed1f14b9bddd84ac091a8a22a8 doc_id: 951841 cord_uid: fxebqm7k Abstract Objective: Evaluate the prevalence and characteristics of olfactory or gustatory dysfunction in COVID-19 patients Study Design: Multicenter Case Series Setting: 5 tertiary care hospitals (3 in China, 1 in France, 1 in Germany) Subjects and Methods: 394 PCR confirmed COVID-19 positive patients were screened, and those with olfactory or gustatory dysfunction were included. Data including demographics, COVID-19 severity, patient outcome, and the incidence and degree of olfactory and/or gustatory dysfunction were collected and analyzed. The Questionnaire of Olfactory Disorders (QOD) and Visual Analogue Scale (VAS) were used to quantify olfactory and gustatory dysfunction respectively. All subjects at one hospital (Shanghai) without subjective olfactory complaints underwent objective testing. Results: Of 394 screened subjects, 161 (41%) reported olfactory and/or gustatory dysfunction and were included. Incidence of olfactory and/or gustatory disorders in Chinese (n=239), German (n=39) and French (n=116) cohorts were 32%, 69%, and 49% 138 respectively. The median age of included subjects was 39 years old, 92/161 (57%) were male, and 10/161 (6%) were children. Of included subjects, 10% had only olfactory or gustatory symptoms, and 19% had olfactory and/or gustatory complaints prior to any other COVID-19 symptom. Of subjects with objective olfactory testing, 10/90 demonstrated abnormal chemosensory function despite reporting normal subjective olfaction. 43% (44/102) of subjects with follow-up showed symptomatic improvement in olfaction or gustation. Conclusions: Olfactory and/or gustatory disorders may represent early or isolated symptoms of SARS-CoV-2 infection. They may serve as a useful additional screening criterion, particularly for the identification of patients in the early stages of infection. The global spread of SARS-CoV-2 is fast-moving and ongoing, with more than three 166 million cases reported across 214 countries and regions. 1 The main clinical symptoms 167 of COVID-19 patients are fever, dry cough, and fatigue. Patients may also present with 168 less typical symptoms including nasal congestion, rhinorrhea, sore throat, myalgia, and 169 diarrhea. 2 Recently reports from a number of countries indicate that olfactory or 170 gustatory dysfunction may also be one of the initial presenting symptoms in a large 171 number of COVID-19 patients. 3 A study of COVID-19 inpatients in Wuhan 172 demonstrated that 5.1% (11/214) patients experienced hyposmia, and 5.6% (12/214) 173 patients exhibited hypogeusia. 4 An Italian study found that 33.9% of COVID-19 174 confirmed inpatients presented with at least one olfactory or gustatory symptom. 5 A 175 study of patients with influenza-like symptoms showed that COVID-19 positive 176 patients have a high prevalence of olfactory or gustatory disorders compared with 177 COVID-19 negative patients. 6 Olfactory and gustatory disorders were also found to be 178 prevalent symptoms in COVID-19 patients in a multicenter European study. 7 The 179 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) 180 developed an anosmia reporting tool that was opened to contributors on March 26,2020 181 and the initial findings were reported on 237 patients worldwide. There are now over 182 800 patients submitted through this tool. Anosmia was the sentinel symptom in over 183 25% of the patients and occurred in over two-thirds of the patients. 8 Some patients with 184 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 mild symptoms may only have changes in olfaction or gustation and so may be 185 overlooked in screening and testing efforts, leading to further disease spread. 186 However, the documented prevalence of olfactory or gustatory disorders differs greatly 187 between studies, and little is known about how this may vary based on factors such as 188 age, disease severity, and between multiple different countries and/or ethnic 189 populations. To remedy this, we studied the association between olfactory and 190 gustatory complaints and early SARS-CoV-2 infections at 5 hospitals in China, 191 Germany France) initially diagnosed by RT-PCR from oro-or nasopharyngeal swab specimens 202 were screened. All 394 patients were asked about loss of olfaction and/or gustation and 203 161 patients presenting with olfactory and/or gustatory dysfunction were identified and 204 enrolled in this study, with final follow-up obtained on April 5 th , 2020. Hospitals 205 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 included in the study were as follows: For the test, three disposable cotton swabs dipped in each of these stimuli were placed 224 1-2 cm below the front nostril of the subjects, who were instructed to smell 3 times. A 225 VAS of gustatory intensity was used to assess the presence and degree of hypogeusia. 226 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 Disease severity was classified as follows. Asymptomatic patients indicates that there 227 were no clinically identifiable or self-perceived signs or symptoms of infection at the 228 time of positive SARS-CoV-2 PCR testing. Patients classified as mild presented with 229 only low fever, mild cough, slight fatigue, and no evidence of pneumonia on CT 230 imaging. Patients classified as moderate had fever and respiratory symptoms, and 231 imaging showed evidence of pneumonia. Patients classified as severe had dyspnea, 232 respiratory frequency ≥30/min, blood oxygen saturation ≤93%, partial pressure of 233 arterial oxygen to fraction of inspired oxygen ratio ≤300mmHg or pulmonary CT 234 imaging showing at least a 50% increase in infiltrate volume over 24-48 hours. Patients 235 classified as critical had respiratory failure, septic shock, and/or multiple organ 236 dysfunction or failure. 2 237 Clinical, treatment, and outcome data were obtained from data collection forms in the 238 electronic medical records. The data were analyzed and reviewed by a team of trained 239 physicians. The recorded information included demographic data, comorbidities, 240 severity classification, patient outcomes, the degree of olfactory or gustatory loss and 241 the incidence of the symptom in COVID-19 patients. A descriptive analysis was 242 performed. Categorical variables were described as frequency rates and percentages, 243 and continuous variables were described using mean, median, standard deviation (SD) 244 and interquartile range (IQR) values. A pairwise comparison of data from the three 245 countries was made to assess for demographic heterogeneity and examine differences 246 in the prevalence and characteristics of olfactory and gustatory symptoms. Independent 247 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 group t tests and chi-square tests were used for continuous variables and categorical 248 variables, respectively. Fisher exact test was used when the data were limited. All 249 statistical analyses were performed using SPSS (Statistical Package for the Social 250 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 respectively. The severity classification among all COVID-19 patients in France was 269 Among the 161 included patients who had sudden olfactory or gustatory loss, median 271 age was 38.8±17.6 years (IQR, 23-53 years) and 92/161 (57%) were male. Distribution 272 of age in these enrolled patients was significantly different between China and the two 273 The percentage of patients presenting with olfactory or gustatory disorders as their first 288 symptom of infection in China, Germany and France were 23%, 15% and 15%, 289 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 respectively. Olfactory or gustatory symptoms occurred simultaneously with classic 290 COVID-19 symptoms such as fever, cough, sore throat and diarrhea in 30 of 156 (19%) 291 patients (Table 1) . A single patient developed hearing loss during the course of their 292 In a subset of patients we were able to evaluate olfactory or gustatory function using 294 the olfactory VAS (n=113), the gustatory VAS (n=46) and the QOD (n=60). The mean 295 VAS scores of patients with olfactory or gustatory dysfunction were 3.60±3.62 (IQR 296 0-7) and 4.46±2.90 (IQR 2.25-6), respectively. The mean scores of QOD-QoL (quality 297 of life) were 37%±23% (IQR 18%-49%), QOD-DS (socially desired statements) were 298 41%±15% (IQR 32%-50%), and QOD-P (parosmic statements) were 40%±30% (IQR 299 17%-60%) ( Table 2) . Of the 90 patients without subjective olfactory dysfunction in the 300 Shanghai, China cohort who were tested with the three chemosensory stimuli, 10 (9 301 adults and 1 child) showed abnormal chemosensory function. Eight of the ten patients 302 could not smell the three stimuli at all, while the other two could smell an odor but 303 could not distinguish the type of odor. These eight patients who could not perceive 304 vinegar and 75% ethanol may also have a trigeminal deficit. 305 Of the 102 patients for whom follow-up data was available (time range for follow-up 306 was 3 weeks), 44 of 102 (43%) patients had improvement of their olfactory or gustatory 307 dysfunction, with the other 58 (57%) showing no improvement (including 3 deaths 308 among the critical cases). There was no significant difference in the outcome of 309 olfactory and/or gustatory disorders between Chinese and French COVID-19 patients 310 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100198 doi: medRxiv preprint (P=0.715). Follow-up data was not available for the German cohort, and was available 311 for only 25 patients in the French cohort (Table 1) . 312 Of 27 COVID-19 positive children who were screened (range of age 6-17 years), 10 313 (37%) children with olfactory or gustatory dysfunction were included. The age of these 314 10 patients ranged from 15 to 17 years old, and six of 10 (60%) were male. Seven 315 children (3 mild cases, 4 moderate cases) had both hyposmia and hypogeusia. Only 316 eight of the 10 patients were able to report the sequencing of their symptoms. Of these 317 eight, two patients (25%) had hyposmia and/or hypogeusia as their only symptom, and 318 both were found to have infected their family member prior to diagnosis. An additional 319 hospitalized child who did not report any subjective olfactory symptoms was also found 320 to have subclinical olfactory dysfunction when tested with the olfactory reagents. Three 321 of 9 (33%) children showed total symptomatic improvement during the observation 322 period. Follow-up was not obtained for one child in the German cohort (Table 3) . 323 324 This study systematically studied the incidence and characteristics of sensory 326 dysfunction among COVID-19 patients. It is the first to examine olfactory and/or 327 gustatory dysfunction in infected children. In our cohort of 394 COVID-19 patients, 41% 328 presented with olfactory and/or gustatory disorders, of whom approximately half were 329 mildly symptomatic. The incidence of olfactory or gustatory disorders in COVID-19 330 patients in Germany (69%) and France (49%) were significantly higher than in China 331 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 (32%, P＜0.001 and P=0.002 respectively). A recent study also found that different 332 variants of SARS-CoV-2 are predominant outside of East Asia ("Type A" and "Type 333 C") compared to within East Asia ("Type C"). 10 It is possible that phenotypic 334 characteristics -including incidence of olfactory and gustatory disorders -may differ 335 between these variants. There is also the possibility that the incidence of olfactory or 336 gustatory disorders may vary based on ethnicity. However, given that there was also a 337 smaller but significant different between the German and French groups (P=0.029), it 338 is possible that the differences reflect other sources of heterogeneity between the groups 339 such as subject age, as the median age of German and French groups showed significant 340 difference with Chinese group (P=0.001 and P＜0.001 respectively). Interestingly, the 341 distribution of COVID-19 disease severity among included subjects varied significantly 342 when comparing the three country cohorts to each other, which may indicate that 343 presence of olfactory or gustatory symptoms are not related to overall disease severity. 344 Olfactory or gustatory symptoms were the first and only symptoms in 10% of patients, 345 and 19% of patients experienced olfactory or gustatory dysfunction prior to any other 346 COVID-19 symptoms. In addition, 25% of children had only olfactory or gustatory 347 symptoms at COVID-19 presentation. This indicates that olfactory or gustatory 348 disorders are early identifiers of COVID-19 in a subset of patients, and thus has 349 important implications for patient screening and disease control. 350 Despite still being infectious, a significant portion of COVID-19 patients may be 351 minimally or atypically symptomatic early in the course of the disease, with one study 352 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 finding that less than 50% of early patients are febrile. 11 These patients may be missed 353 by screening initiatives focused on "classic" symptoms such as fever and cough, 354 delaying diagnosis, undermining triage and quarantine efforts, and leading to higher 355 rates of disease transmission. At least two mild patients in our study who presented with 356 applied. Notably, there were 10 subjects (9 adults and 1 child) who reported that they 364 had no olfactory dysfunction, but demonstrated signs of subclinical hyposmia when 365 exposed to three chemosensory stimuli. This may suggest that screening based on self-366 reported symptoms alone is not sufficient, considering the relatively high degree of 367 erroneous self-ratings with respect to the chemical senses. 12 However, it is not certain 368 if any of these patients had unrecognized pre-existing smell and/or taste disorders 369 unrelated to Recent studies have shed light on the mechanisms that may underlie the loss of olfaction 371 or gustation. SARS-CoV-2 has been found to replicate particularly well in the nose, 372 with high viral loads detected there soon after symptom onset. 13 ACE2 -the main host 373 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 cell receptor of SARS-CoV-2 -and TMPRSS2 -a cell surface protease involved in 374 SARS-CoV-2 cell entry -are highly expressed in a variety of olfactory epithelial cell 375 types, raising the possibility that viral invasion of these cells may lead to anosmia. 14,15 376 It has also been suggested that transcribiform viral spread and infection of more 377 proximal elements of the olfactory pathway via CNS ACE2 receptors may also 378 contribute to olfactory dysfunction. 16, 17 Alternatively, it is possible that at least some of 379 the olfactory dysfunction is conductive -secondary to nasal congestion, swelling, or 380 inflammation preventing olfactory molecules from reaching the olfactory cleft -rather 381 than sensorineural. 18 This may be particularly true in the subset of patients who showed 382 improvement of their olfactory dysfunction on follow-up, though further research is 383 needed. ACE2 is also highly expressed on the oral mucosa and tongue, representing a 384 potential mechanism for gustatory dysfunction. 19 385 In addition to the much more common olfactory and gustatory sensory deficits, we 386 identified new onset hearing loss in one severely ill patient. While more research is 387 needed, this suggests that we should also be alert for other sensory deficits in addition 388 to hyposmia and dysgeusia, particularly given SARS-CoV-2's ability to invade the 389 CNS. 390 391 As with any retrospective study, the conclusions that can be drawn are limited by the 393 heterogeneous nature of the data available. Likewise, due to the impact of the COVID-394 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 19 pandemic and the difficulties inherent to a retrospective multi-institutional and 395 international study, there are differences in data collection methods and patient 396 populations between institutions that make drawing direct comparisons for some 397 measures more difficult. Olfactory and gustatory function have not been measured 398 psychophysically in COVID-19 positive patients, so it is possible that patients may have 399 confused gustatory and retronasal olfactory function, which would result in biased 400 ratings of olfactory or gustatory function. In addition, the subjective perception of 401 olfactory function is confounded by nasal breathing. Finally, symptom timeline often 402 relies on patient report of their symptoms and is subject to recall bias. To address these 403 issues, future prospective studies are necessary. 404 405 Olfactory and/or gustatory dysfunction may represent early or even the only symptom 407 of SARS-CoV-2 infection in both adults and children. As such, they may serve as 408 important screening criteria for identifying otherwise oligosymptomatic or atypically 409 symptomatic patients missed by other screening measures. We recommend that 410 questions related to olfactory and gustatory changes be added to routine screening 411 measures to help identify these patients prior to further disease transmission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 May 16, . . https://doi.org/10.1101 May 16, /2020 doi: medRxiv preprint b three patients in France could not remember the date of onset of olfactory or gustatory 506 dysfunction. c the patients'improvement in Germany is unavailable. d only 25 patients 507 were followed in France. e three critical patients died of COVID-19. f statistics for 508 China(77 cases) and France(25 cases) . 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 Non-improved 6/9(67%) b Abbreviations: SD, standard deviation; IQR, interquartile range a two children could 584 not remember the date of onset of olfactory or gustatory dysfunction. b follow-up was 585 not obtained for one child in the German cohort. 586 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 16, 2020 . . https://doi.org/10.1101 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns JHU)-Cumulative Confirmed Cases Diagnosis and treatment plan for pneumonitis associated with new coronavirus infection 425 (trial version 7): General Office of the National Health Council and the Office of the State 426 Administration of Traditional Chinese Medicine Loss of sense of smell as marker of COVID-19 infection. ENT UK at The Royal College of 430 Surgeons of England Neurologic Manifestations of Hospitalized Patients With 434 Coronavirus Disease Self-reported olfactory and taste disorders in SARS-437 CoV-2 patients: a cross-sectional study Association of chemosensory 440 dysfunction and Covid-19 in patients presenting with influenza-like symptoms Olfactory and gustatory dysfunctions as 444 a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a 445 multicenter European study COVID-19 Anosmia Reporting 448 Tool: Initial Findings Olfactory dysfunction and daily life Phylogenetic network analysis of SARS-CoV-2 452 genomes Early Transmission Dynamics in Wuhan, China SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 460 Infected Patients Non-neural expression of SARS-462 CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in 463 COVID-19 patients SARS-CoV-2 entry factors are highly expressed in 465 nasal epithelial cells together with innate immune genes Evidence of the COVID-19 Virus Targeting the CNS Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms Sendai Virus Induces Persistent Olfactory Dysfunction in a 471 Murine Model of PVOD via Effects on Apoptosis, Cell Proliferation, and Response to 472 Sudden and Complete Olfactory Loss Function as a 475 Possible Symptom of COVID-19 High expression of ACE2 receptor of 2019-nCoV on the 478 epithelial cells of oral mucosa Characteristics of COVID-19 Patients Presenting with Olfactory/ 501 Gustatory Dysfunction Abbreviations: SD, standard deviation; IQR, interquartile range. a two patients in 504 China could not remember the date of onset of olfactory or gustatory dysfunction